Xuxu Gou

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 14

Top Topics

Molecular Dynamics Simulations

Endoplasmic Reticulum

Protein Protein

Top Venues

Science (New York, N.Y.)

Cancer research

Molecular cancer therapeutics

Molecular & cellular oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Lei Lu, Xuxu Gou, Sophia K Tan, Samuel I Mann, Hyunjun Yang, Xiaofang Zhong, Dimitrios Gazgalis, Jesús Valdiviezo, Hyunil Jo, Yibing Wu, Morgan E Diolati, Alan Ashworth, Nicholas F Polizzi, William F DeGrado
De novo design of drug-binding proteins with predictable binding energy and specificity. Science (New York, N.Y.) 384 (6691) (2024)
Lei Lu, Xuxu Gou, Sophia K Tan, Samuel I Mann, Hyunjun Yang, Xiaofang Zhong, Dimitrios Gazgalis, Jesús Valdiviezo, Hyunil Jo, Yibing Wu, Morgan E Diolati, Alan Ashworth, Nicholas F Polizzi, William F DeGrado
De novo design of drug-binding proteins with predictable binding energy and specificity. Science (New York, N.Y.) 384 (6691) (2024)
Lei Lu, Xuxu Gou, Sophia K Tan, Samuel I Mann, Hyunjun Yang, Xiaofang Zhong, Dimitrios Gazgalis, Jesús Valdiviezo, Hyunil Jo, Yibing Wu, Morgan E Diolati, Alan Ashworth, Nicholas F Polizzi, William F DeGrado
De novo design of drug-binding proteins with predictable binding energy and specificity. Science (New York, N.Y.) 384 (6691) (2024)
Lei Lu, Xuxu Gou, Sophia K Tan, Samuel I Mann, Hyunjun Yang, Xiaofang Zhong, Dimitrios Gazgalis, Jesús Valdiviezo, Hyunil Jo, Yibing Wu, Morgan E Diolati, Alan Ashworth, Nicholas F Polizzi, William F DeGrado
De novo design of drug-binding proteins with predictable binding energy and specificity. Science (New York, N.Y.) 384 (6691) (2024)
Lei Lu, Xuxu Gou, Sophia K Tan, Samuel I Mann, Hyunjun Yang, Xiaofang Zhong, Dimitrios Gazgalis, Jesús Valdiviezo, Hyunil Jo, Yibing Wu, Morgan E Diolati, Alan Ashworth, Nicholas F Polizzi, William F DeGrado
De novo design of drug-binding proteins with predictable binding energy and specificity. Science (New York, N.Y.) 384 (6691) (2024)
Lei Lu, Xuxu Gou, Sophia K Tan, Samuel I Mann, Hyunjun Yang, Xiaofang Zhong, Dimitrios Gazgalis, Jesús Valdiviezo, Hyunil Jo, Yibing Wu, Morgan E Diolati, Alan Ashworth, Nicholas F Polizzi, William F DeGrado
De novo design of drug-binding proteins with predictable binding energy and specificity. Science (New York, N.Y.) 384 (6691) (2024)
Lei Lu, Xuxu Gou, Sophia K Tan, Samuel I Mann, Hyunjun Yang, Xiaofang Zhong, Dimitrios Gazgalis, Jesús Valdiviezo, Hyunil Jo, Yibing Wu, Morgan E Diolati, Alan Ashworth, Nicholas F Polizzi, William F DeGrado
De novo design of drug-binding proteins with predictable binding energy and specificity. Science (New York, N.Y.) 384 (6691) (2024)
Anran Chen, Beom-Jun Kim, Aparna Mitra, Craig T Vollert, Jonathan T Lei, Diana Fandino, Meenakshi Anurag, Matthew V Holt, Xuxu Gou, Jacob B Pilcher, Matthew P Goetz, Donald W Northfelt, Susan G Hilsenbeck, C Gary Marshall, Marc L Hyer, Robert Papp, Shou-Yun Yin, Carmine De Angelis, Rachel Schiff, Suzanne A W Fuqua, Cynthia X Ma, Charles E Foulds, Matthew J Ellis
PKMYT1 is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Molecular cancer therapeutics (2024)
Lei Lu, Xuxu Gou, Sophia K Tan, Samuel I Mann, Hyunjun Yang, Xiaofang Zhong, Dimitrios Gazgalis, Jesús Valdiviezo, Hyunil Jo, Yibing Wu, Morgan E Diolati, Alan Ashworth, Nicholas F Polizzi, William F DeGrado
De novo design of drug-binding proteins with predictable binding energy and specificity. Science (New York, N.Y.) 384 (6691) (2024)
Anran Chen, Beom-Jun Kim, Aparna Mitra, Craig T Vollert, Jonathan T Lei, Diana Fandino, Meenakshi Anurag, Matthew V Holt, Xuxu Gou, Jacob B Pilcher, Matthew P Goetz, Donald W Northfelt, Susan G Hilsenbeck, C Gary Marshall, Marc L Hyer, Robert Papp, Shou-Yun Yin, Carmine De Angelis, Rachel Schiff, Suzanne A W Fuqua, Cynthia X Ma, Charles E Foulds, Matthew J Ellis
PKMYT1 is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Molecular cancer therapeutics (2024)
Xuxu Gou, Beom-Jun Kim, Meenakshi Anurag, Jonathan T Lei, Meggie N Young, Matthew V Holt, Diana Fandino, Craig T Vollert, Purba Singh, Mohammad A Alzubi, Anna Malovannaya, Lacey Elizabeth Dobrolecki, Michael T Lewis, Shunqiang Li, Charles E Foulds, Matthew J Ellis
Kinome reprogramming is a targetable vulnerability in ESR1 fusion-driven breast cancer. Cancer research (2023)
Meenakshi Anurag, Eric J Jaehnig, Karsten Krug, Jonathan T Lei, Erik J Bergstrom, Beom-Jun Kim, Tanmayi D Vashist, Anh Minh Tran Huynh, Yongchao Dou, Xuxu Gou, Chen Huang, Zhiao Shi, Bo Wen, Viktoriya Korchina, Richard A Gibbs, Donna M Muzny, Harsha Vardhan Doddapaneni, Lacey Elizabeth Dobrolecki, Henry Rodriguez, Ana I Robles, Tara Hiltke, Michael T Lewis, Julie R Nangia, Maryam Nemati Shafaee, Shunqiang Li, Ian S Hagemann, Jeremy Hoog, Bora Lim, C Kent Osborne, D R Mani, Michael A Gillette, Bing Zhang, Gloria V Echeverria, George Miles, Mothaffar F Rimawi, Steven A Carr, Foluso O Ademuyiwa, Shankha Satpathy, Matthew J Ellis
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. Cancer discovery 12 (11) (2022)
Xuxu Gou, Meenakshi Anurag, Jonathan T Lei, Beom-Jun Kim, Purba Singh, Sinem Seker, Diana Fandino, Airi Han, Saif Rehman, Jianhong Hu, Viktoriya Korchina, Harshavardhan Doddapaneni, Lacey Elizabeth Dobrolecki, Nicholas Mitsiades, Michael T Lewis, Alana L Welm, Shunqiang Li, Adrian V Lee, Dan R Robinson, Charles E Foulds, Matthew J Ellis
Transcriptional reprogramming differentiates active from inactive ESR1 fusions in endocrine therapy-refractory metastatic breast cancer. Cancer research (2021)
Jonathan T Lei, Xuxu Gou, Matthew J Ellis
ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer. Molecular & cellular oncology 5 (6) (2018)